{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:15:05Z","timestamp":1781136905483,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":4239,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1093\/annonc\/mdm539","type":"journal-article","created":{"date-parts":[[2007,11,28]],"date-time":"2007-11-28T01:59:19Z","timestamp":1196215159000},"page":"853-860","source":"Crossref","is-referenced-by-count":42,"title":["Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10\/00"],"prefix":"10.1016","volume":"19","author":[{"given":"G.","family":"Fountzilas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Dafni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Linardou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.P.","family":"Kalofonos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Briasoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Pectasides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Samantas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bafaloukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.P.","family":"Stathopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Karina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Skarlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Pisanidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Papakostas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Markopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tzorakoeleftherakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Dimitrakakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Makrantonakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Xiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Polichronis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Varthalitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Karanikiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1093\/annonc\/mdm539_bb0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/annonc\/mdl498","article-title":"Estimates of the cancer incidence and mortality in Europe in 2006","volume":"18","author":"Ferlay","year":"2007","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1093\/annonc\/mdm539_bb0015","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJMsr070105","article-title":"The decrease in breast-cancer incidence in 2003 in the United States","volume":"356","author":"Ravdin","year":"2007","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mdm539_bb0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1634\/theoncologist.6-suppl_3-30","article-title":"Theoretical concepts and the emerging role of taxanes in adjuvant therapy","volume":"6","author":"Norton","year":"2001","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdm539_bb0025","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S1470-2045(05)70424-1","article-title":"Selection of adjuvant chemotherapy for treatment of node-positive breast cancer","volume":"6","author":"Trudeau","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdm539_bb0030","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jama.1995.03520310040027","article-title":"Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results","volume":"273","author":"Bonadonna","year":"1995","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdm539_bb0035","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","article-title":"Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer","volume":"21","author":"Henderson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm539_bb0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1200\/JCO.1999.17.1.93","article-title":"Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy","volume":"17","author":"Hudis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm539_bb0045","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1159\/000011903","article-title":"Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and 10 positive axillary lymph nodes. A feasibility study","volume":"55","author":"Fountzilas","year":"1998","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdm539_bb0050","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm539_bb0055","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdi366","article-title":"Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group","volume":"16","author":"Fountzilas","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm539_bb0060","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm539_bb0065","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/jama.279.18.1489","article-title":"CONSORT: an evolving tool to help improve the quality of reports of randomized controlled trials","volume":"279","author":"Moher","year":"1998","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdm539_bb0070","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","article-title":"Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer","volume":"90","author":"Budman","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdm539_bb0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3233\/BD-2001-14104","article-title":"Dosage parameters in chemotherapy of breast cancer","volume":"14","author":"Hryniuk","year":"2001","journal-title":"Breast Dis"},{"key":"10.1093\/annonc\/mdm539_bb0080","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1200\/JCO.2003.12.068","article-title":"Mathematics and Oncology: a match for life?","volume":"21","author":"Piccart-Gebhart","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm539_bb0085","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/annonc\/mdl355","volume":"18","author":"Piedbois","year":"2007","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdm539_bb0090","volume":"94","author":"Eiermann","year":"2005","journal-title":"Breast Can Res Treat"},{"issue":"18 Suppl","key":"10.1093\/annonc\/mdm539_bb0095","volume":"24","author":"Crown","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm539_bb0100","doi-asserted-by":"crossref","first-page":"8340","DOI":"10.1200\/JCO.2005.02.8621","article-title":"Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy","volume":"23","author":"Burstein","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm539_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm539_bb0110","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jnci\/djk028","article-title":"Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy","volume":"99","author":"Hershman","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdm539_bb0115","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/jnci\/dji398","article-title":"Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial","volume":"97","author":"Venturini","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdm539_bb0120","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1634\/theoncologist.10-10-780","article-title":"Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin","volume":"10","author":"Gl\u00fcck","year":"2005","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdm539_bb0125","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1200\/JCO.2003.08.137","article-title":"Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group","volume":"21","author":"Crump","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm539_bb0130","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1200\/JCO.2005.05.029","article-title":"Risk of myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide","volume":"23","author":"Praga","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419418334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419418334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/19\/5\/853\/398768\/mdm539.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T13:33:52Z","timestamp":1582205632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419418334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0923753419418334"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdm539","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}